why choose us

First received: November 07, 2022

Clinical Trial: A Study of LOXO-435 in Participants With Cancer With a Change in a Gene Called FGFR3

Study Status: Completed

Recruit Status: RECRUITING

Condition: Urinary Bladder Neoplasms

Study Type: INTERVENTIONAL


Official Title: An Open-Label, Multicenter Study of LOXO-435 (LY3866288) In Advanced Solid Tumor Malignancies With FGFR3 Alterations

Brief Summary: The main purpose of this study is to learn more about the safety, side effects, and effectiveness of LOXO-435.LOXO-435 may be used to treat cancer of the cells that line the urinary system and other solid tumor cancers that have a change in a particular gene (known as the FGFR3 gene).Participation could last up to 30 months (2.5 years) and possibly longer if the disease does not get worse.

Read more